Research Reports | Market Assessment
October 2015

Prostate Cancer | Pharmacor | G7 | 2015

Last Updated 22 October 2015
The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following the launch of five efficacious therapies since 2010, and the hormonal agents Zytiga (Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone) and Xtandi (Medivation/Astellas Pharma’s enzalutamide) compete fiercely in this setting. The prostate cancer drug development pipeline is dynamic, and agents in late-phase development span a wide range of drug classes. The expected launch of several emerging therapies for prostate cancer over 2014-2024 will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports